STAAR Surgical (NASDAQ:STAA) Shares Gap Down After Earnings Miss

STAAR Surgical Company (NASDAQ:STAA) shares gapped down before the market opened on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $18.92, but opened at $17.67. STAAR Surgical shares last traded at $19.41, with a volume of 507,661 shares.

The medical instruments supplier reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.51). The firm had revenue of $57.80 million for the quarter, compared to analyst estimates of $75.54 million. STAAR Surgical had a negative return on equity of 16.06% and a negative net margin of 41.79%.STAAR Surgical’s revenue for the quarter was up 18.0% on a year-over-year basis.

Key STAAR Surgical News

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: China and product demand: Management highlighted strong sales growth in China and continued adoption of the EVO ICL family, supporting revenue growth (+18% YoY in Q4). Staar Surgical Co (STAA) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Margin recovery and cash position: Gross profit expanded and cost of sales declined, which helped margins; cash and equivalents rose to ~$153M, reducing short‑term liquidity risk. These operational improvements give scope for recovery if sales normalize. STAAR Surgical Stock Falls on Q4 2025 Earnings (Quiver)
• Positive Sentiment: Insider and institutional appetite: Recent insider/institutional purchases and at least one recent Buy rating from Jefferies indicate some investors see longer‑term upside. That support can limit downside if execution improves. STAAR Surgical Stock Falls on Q4 2025 Earnings (Quiver)
• Neutral Sentiment: Management communication: The company issued a shareholder letter and co‑CEOs addressed investors after the miss; leadership transition/context may help transparency but leaves near‑term execution questions unanswered. STAAR Surgical Issues Shareholder Letter (BusinessWire)
• Negative Sentiment: Earnings and revenue miss: Q4 revenue came in at $57.8M (vs. consensus ~ $75M) and EPS was a -$0.37 miss of analyst expectations, prompting the share drop and signaling larger near‑term demand headwinds than modeled. STAAR Surgical Q4 Earnings Summary (MarketBeat)
• Negative Sentiment: Analyst reaction: Stifel cut its price target to $18 and set a Hold, and other firms flagged short‑term revenue headwinds — analyst downgrades/target cuts add selling pressure and lower near‑term upside. Stifel Lowers PT to $18 (Benzinga)
• Negative Sentiment: Investor concern over execution: Coverage and commentary emphasize the company’s operating loss and widened net loss despite revenue growth, keeping focus on when profitability and top‑line momentum will sustainably return. Co‑CEOs Address Shareholders After Poor Earnings (MassDevice)

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on STAA shares. BTIG Research reiterated a “neutral” rating on shares of STAAR Surgical in a report on Tuesday, January 6th. Canaccord Genuity Group reduced their price objective on STAAR Surgical from $30.75 to $22.00 and set a “hold” rating on the stock in a research note on Thursday, January 15th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Tuesday, January 6th. Stifel Nicolaus lowered their target price on STAAR Surgical from $19.00 to $18.00 and set a “hold” rating for the company in a research note on Wednesday. Finally, Wedbush started coverage on STAAR Surgical in a research report on Tuesday, February 3rd. They issued a “neutral” rating and a $26.00 price target on the stock. One research analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, STAAR Surgical currently has an average rating of “Reduce” and an average price target of $20.78.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 336,946 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The shares were purchased at an average price of $21.62 per share, with a total value of $7,284,772.52. Following the completion of the acquisition, the insider directly owned 15,356,437 shares of the company’s stock, valued at $332,006,167.94. This represents a 2.24% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have acquired a total of 434,138 shares of company stock worth $9,424,176 in the last three months. Insiders own 0.59% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of STAAR Surgical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock valued at $518,000 after acquiring an additional 1,267 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in STAAR Surgical by 33.4% in the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock valued at $9,606,000 after purchasing an additional 136,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in STAAR Surgical by 11.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock valued at $2,175,000 after purchasing an additional 12,841 shares during the last quarter. CWM LLC raised its holdings in STAAR Surgical by 74.1% during the second quarter. CWM LLC now owns 1,563 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 665 shares in the last quarter. Finally, AlphaQuest LLC boosted its holdings in shares of STAAR Surgical by 197.4% in the 2nd quarter. AlphaQuest LLC now owns 10,879 shares of the medical instruments supplier’s stock valued at $183,000 after buying an additional 7,221 shares in the last quarter. 96.70% of the stock is owned by institutional investors and hedge funds.

STAAR Surgical Trading Down 0.5%

The firm’s fifty day moving average price is $19.97 and its 200-day moving average price is $24.19. The firm has a market cap of $936.60 million, a price-to-earnings ratio of -9.66 and a beta of 1.05.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.